0001104659-13-081324.txt : 20131105 0001104659-13-081324.hdr.sgml : 20131105 20131105204855 ACCESSION NUMBER: 0001104659-13-081324 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131105 FILED AS OF DATE: 20131105 DATE AS OF CHANGE: 20131105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-975-4820 MAIL ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAKIANATHAN DEEPIKA CENTRAL INDEX KEY: 0001270734 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 131194397 MAIL ADDRESS: STREET 1: 3000 SAND HILL RD, BLDG 1, STE 135 STREET 2: C/O DELPHI VENTURES CITY: MENLO PARK STATE: CA ZIP: 94025 3 1 a3.xml 3 X0206 3 2013-11-05 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001270734 PAKIANATHAN DEEPIKA DELPHI VENTURES, 3000 SAND HILL RD, BLDG 1, STE 135 MENLO PARK CA 94025 1 0 0 0 Series B Convertible Preferred Stock Common Stock 1500500 I By Delphi Ventures VIII, L.P. Series B Convertible Preferred Stock Common Stock 14652 I By Delphi Bioinvestments VIII, L.P. Series B-1 Convertible Preferred Stock Common Stock 272818 I By Delphi Ventures VIII, L.P. Series B-1 Convertible Preferred Stock Common Stock 2663 I By Delphi Bioinvestments VIII, L.P. The Series B Convertible Preferred Stock is convertible into Common Stock on a 1-for-3.3 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein. The Series B-1 Convertible Preferred Stock is convertible into Common Stock on a 1-for-3.3 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. /s/ Deepika R.Pakianathan 2013-11-05